Gilead Invests In Synthetic Biology Partnership For Next Gen CAR-Ts
Adapted Cells Can Sense Tumor Microenvironment
Gilead's Yescarta is set to exceed sales of $1bn for the first time this year, but could face 'off the shelf' competition soon. • Source: Gilead 
